Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
VIAV
HIV/AIDS
Framework programme: 6
Call: 2
Project number:
LSHP-CT-2004-012188
EC contribution: € 1,000,000
Duration: 24 months
Type: STREP
Starting date: 1 January 2005
Graphic element Very Innovative AIDS Vaccine
Keywords: Infections; vaccines; immunology; AIDS; HIV; Tat protein; Env; Tat-Env complex; HIV entry; HIV neutralising antibodies

Summary:

The goal of the VIAV programme is to develop a novel, broadly effective HIV/AIDS vaccine based on HIV Tat and Env protein complexes. VIAV is built upon an international consortium of European experts in the fields of HIV/AIDS protein structure and molecular modelling/docking, biochemistry, molecular biology, virology, immunology, vaccine development, GMP production, trial conduction and field studies.

Background:

Results obtained by the VIAV Consortium indicate that the HIV Tat protein increases HIV cell adsorption, infectivity and tropisms by interacting with components of the HIV membrane and envelope protein (Env). Because the interaction between Tat and Env may allow the generation of complex-specific, neutralisation-sensitive epitopes and/or the stabilisation of cryptic and/or transiently exposed Env epitopes, a vaccine based on Tat-Env complexes is likely to generate protective immune responses against vulnerable viral targets.

Aim:

The aim of VIAV is to develop a highly innovative Tat-Env complex-based vaccine capable of inducing cross-clade neutralising antibodies against novel, neutralisation-sensitive Env epitopes to prevent HIV infection and/or AIDS progression. The VIAV aim will be achieved through new antigen design stemming out from novel virological, immunological and modeling data of the VIAV Consortium.

Expected results:

The VIAV project will allow the identification of novel HIV/AIDS vaccine immunogens and formulations for the induction of broad immunity against HIV. Tat-Env complexes will be characterised and used to immunise small animals, where vaccination is expected to be safe and immunogenic. Neutralising antibody responses will be also characterised and novel neutralisation-sensitive, complex-induced epitopes will be identified.

Potential applications:

The VIAV programme will bring specific contributions to AIDS vaccine research and development in terms of innovative vaccine formulations. In particular, the exploitation of novel vaccine formulations based on newly-identified/produced protein complexes that are potentially relevant in the context of HIV natural infection may directly result from VIAV. VIAV is an ambitious project that will fit in the scientific effort aimed at developing innovative AIDS candidate vaccines, based on combinations of regulatory and structural viral proteins. VIAV is also linked to the AIDS Vaccine Integrated Project (AVIP), recently awarded by the EU Commission, for future product development and clinical testing.

Coordinator:

Flavia Ferrantelli
Istituto Superiore di Sanità
Viale Regina Elena 299
00161 Rome
Italy
Tel: +39 06 4990 3209
Fax: +39 06 4990 3002
E-mail: flaviafr@iss.it
Website: http://www.iss.it

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Banci LuciaConsorzio Interuniversitario Risonanze Magnetiche di Metalloproteine
Paramagnetiche
Via L. Sacconi 6
IT-50019 Sesto Fiorentino
Italy
Tel: +39 055 457 4263
Fax: +39 055 457 4253
E-mail: banci@cerm.unifi.it
Website: http://www.cerm.unifi.it
3Eva Maria FenyoLunds Universitet
Solvegatan 23
SE-22362 Lund
Sweden
Tel: +46 46 17 3275
Fax: +46 46 17 6033
E-mail: Eva_maria.fenyo@mmb.lu.se
Website: http://www.lu.se
4Dag HellandUniversitetet I Bergen
Museplass 1
5020 Bergen
Norway
Tel: +47 55 58 45 19
Fax: +47 55 58 96 83
E-mail: dag.helland@mbi.uib.no
Website: http://www.uib.no
5Elisa GargiuloDIATHEVA srl
Viale Piceno 137/F
IT-61032 Fano
Italy
Tel: +39 0721 830 605
Fax: +39 0721 837 154
E-mail: r&d@diatheva.com
Website: http://www.diatheva.com

 
 
top
Graphic element